MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Alterations in 14-3-3 protein phosphorylation as a biomarker for neurodegeneration

    T. Yacoubian, X. Chi, G. Cutter, M. McFerrin (Birmingham, AL, USA)

    Objective: To examine whether 14-3-3 phosphorylation is altered in Parkinson's disease and other neurodegenerative disorders. Background: 14-3-3 proteins are a highly conserved family of proteins…
  • 2016 International Congress

    A novel single molecule imaging approach to detect individual protein oligomers in CSF from patients with Parkinson’s disease (PD)

    S. Gandhi, M.H. Horrocks, S.F. Lee, N.W. Wood, D. Klenerman (London, United Kingdom)

    Objective: (1) To develop an ultra-sensitive method to visualize single amyloid oligomers and (2) to compare the oligomer load in CSF from patients with PD…
  • 2016 International Congress

    Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT

    K. Ma, J. Huang, L. Liu, H. Jiang, X. Xu, C. Han, Y. Shen, Y. Xia, S. Guo, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

    Objective: To evaluate cognitive and depressive behavior in aged mice with heterozygous deletions of vesicular monoamine transporter (VMAT2) or of Dopamine transporter (DAT). Background: VMAT2…
  • 2016 International Congress

    Detailed proteomic analysis of early PD brain highlights altered expression of mitochondrial proteins as an important event in sporadic PD

    S. Gandhi, C.E. Murray, W.E. Heywood, J.L. Holton, K. Mills, T. Revesz (London, United Kingdom)

    Objective: To uncover early pathogenic events occurring prior to neuronal loss and Lewy body formation in human PD brain. Background: In PD, pathological changes spread…
  • 2016 International Congress

    Exosomes-injection to reproduce a mouse model of Parkinson’s disease: A preliminary report

    C. Han, J. Huang, K. Ma, Y. Shen, L. Liu, G. Zhang, X. Xu, J. Li, H. Jiang, S. Guo, Y. Xia, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

    Objective: To explore the pathogenicity of exosomes derived from Parkinson's disease (PD) patients' serum and healthy control's serum in vivo and verify the prion-like propagation…
  • 2016 International Congress

    Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [18F]MNI-659 PET imaging

    D.S. Russell, D.L. Jennings, O. Barret, G.D. Tamagnan, D. Alagille, J.P. Seibyl, K.L. Marek (New Haven, CT, USA)

    Objective: To evaluate the feasibility of [18F]MNI-659 PET, a striatal PDE10A imaging tracer, as a imaging biomarker in PD. Background: PDE10 is highly and specifically…
  • 2016 International Congress

    Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

    W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

    Objective: To investigate the possible disease-association and pathogenic mechanisms of heterozygous PINK1 mutations from a genetic, functional, and structural perspective. Background: It has been postulated…
  • 2016 International Congress

    Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

    F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

    Objective: To characterize the response of cells treated with Gamitrinib-triphenylphosphonium (G-TTP) a mitochondrial targeted inhibitor of the chaperone Hsp90. Background: Upon dissipation of the mitochondrial…
  • 2016 International Congress

    Falls in Parkinson’s disease: Beware the short, slow steps

    A. Lieberman, A. Deep, S. Shafer, T. Lockhart (Phoenix, AZ, USA)

    Objective: To determine if step length influence falls in Parkinson's disease (PD) patients. Background: Falls are major cause of disability in PD. The objective of…
  • 2016 International Congress

    Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease

    A.D. Santana-Vargas, H. Duran-Meza, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, M. Lopez-Ruiz, G. Millan-Rosas, U. Jimenez-Correa (Mexico City, Mexico)

    Objective: To assess utility of Parkinson's disease-cognitive rating scale (PD-CRS) to detect Mild cognitive impairment (MCI) and dementia risk in a Parkinson's disease (PD) subpopulation.…
  • « Previous Page
  • 1
  • …
  • 1429
  • 1430
  • 1431
  • 1432
  • 1433
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley